Suzhou Basecare Medical Corporation Limited

SEHK:2170 Voorraadrapport

Marktkapitalisatie: HK$908.1m

Suzhou Basecare Medical Beheer

Beheer criteriumcontroles 1/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Bo Liang

Algemeen directeur

CN¥3.0m

Totale compensatie

Percentage CEO-salaris84.4%
Dienstverband CEO13.9yrs
Eigendom CEOn/a
Management gemiddelde ambtstermijn6.2yrs
Gemiddelde ambtstermijn bestuur2.6yrs

Recente managementupdates

Here's Why Shareholders May Want To Be Cautious With Increasing Suzhou Basecare Medical Corporation Limited's (HKG:2170) CEO Pay Packet

May 30
Here's Why Shareholders May Want To Be Cautious With Increasing Suzhou Basecare Medical Corporation Limited's (HKG:2170) CEO Pay Packet

Recent updates

Suzhou Basecare Medical (HKG:2170) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Nov 18
Suzhou Basecare Medical (HKG:2170) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Lacklustre Performance Is Driving Suzhou Basecare Medical Corporation Limited's (HKG:2170) Low P/S

Sep 27
Lacklustre Performance Is Driving Suzhou Basecare Medical Corporation Limited's (HKG:2170) Low P/S

Here's Why Shareholders May Want To Be Cautious With Increasing Suzhou Basecare Medical Corporation Limited's (HKG:2170) CEO Pay Packet

May 30
Here's Why Shareholders May Want To Be Cautious With Increasing Suzhou Basecare Medical Corporation Limited's (HKG:2170) CEO Pay Packet

Suzhou Basecare Medical Corporation Limited's (HKG:2170) Shares Leap 27% Yet They're Still Not Telling The Full Story

May 09
Suzhou Basecare Medical Corporation Limited's (HKG:2170) Shares Leap 27% Yet They're Still Not Telling The Full Story

Suzhou Basecare Medical Corporation Limited (HKG:2170) Screens Well But There Might Be A Catch

Mar 22
Suzhou Basecare Medical Corporation Limited (HKG:2170) Screens Well But There Might Be A Catch

Is There An Opportunity With Suzhou Basecare Medical Corporation Limited's (HKG:2170) 47% Undervaluation?

Aug 01
Is There An Opportunity With Suzhou Basecare Medical Corporation Limited's (HKG:2170) 47% Undervaluation?

Lacklustre Performance Is Driving Suzhou Basecare Medical Corporation Limited's (HKG:2170) 27% Price Drop

May 26
Lacklustre Performance Is Driving Suzhou Basecare Medical Corporation Limited's (HKG:2170) 27% Price Drop

Are Investors Undervaluing Suzhou Basecare Medical Corporation Limited (HKG:2170) By 48%?

Jul 20
Are Investors Undervaluing Suzhou Basecare Medical Corporation Limited (HKG:2170) By 48%?

Analyse CEO-vergoeding

Hoe is Bo Liang's beloning veranderd ten opzichte van Suzhou Basecare Medical's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Jun 30 2024n/an/a

-CN¥250m

Mar 31 2024n/an/a

-CN¥221m

Dec 31 2023CN¥3mCN¥3m

-CN¥192m

Sep 30 2023n/an/a

-CN¥176m

Jun 30 2023n/an/a

-CN¥160m

Mar 31 2023n/an/a

-CN¥146m

Dec 31 2022CN¥3mCN¥3m

-CN¥132m

Sep 30 2022n/an/a

-CN¥133m

Jun 30 2022n/an/a

-CN¥135m

Mar 31 2022n/an/a

-CN¥139m

Dec 31 2021CN¥4mCN¥3m

-CN¥144m

Sep 30 2021n/an/a

-CN¥119m

Jun 30 2021n/an/a

-CN¥106m

Mar 31 2021n/an/a

-CN¥490m

Dec 31 2020CN¥8mCN¥1m

-CN¥874m

Sep 30 2020n/an/a

-CN¥1b

Jun 30 2020n/an/a

-CN¥1b

Mar 31 2020n/an/a

-CN¥822m

Dec 31 2019CN¥732kCN¥602k

-CN¥528m

Compensatie versus markt: De totale vergoeding ($USD 421.25K ) Bo } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de Hong Kong markt ($USD 233.47K ).

Compensatie versus inkomsten: De vergoeding van Bo is gestegen terwijl het bedrijf verliesgevend is.

CEO

Bo Liang (43 yo)

13.9yrs

Tenure

CN¥3,046,000

Compensatie

Dr. Bo Liang serves as Executive Director and General Manager at Suzhou Basecare Medical Corporation Limited since December 14, 2010 and serves as its Chairman of the Board since December 14, 2015. Dr. Lia...

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Bo Liang
Chairman of the Board & GM13.9yrsCN¥3.05mgeen gegevens
Lingyin Kong
CTO & Executive Director10.5yrsCN¥1.40mgeen gegevens
Ying Yang
Chief Quality Officer6.2yrsCN¥677.00kgeen gegevens
Lejun Yin
CFO & Joint Company Secretary2yrsgeen gegevensgeen gegevens
Maoshe Rui
Chief Operating Officer7.4yrsCN¥306.00kgeen gegevens
Junchao Jiang
Executive Directorless than a yeargeen gegevensgeen gegevens
Ming Fai Chung
Joint Company Secretary2.3yrsgeen gegevensgeen gegevens

6.2yrs

Gemiddelde duur

43yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 2170 is doorgewinterd en ervaren (gemiddelde ambtstermijn van 6.2 jaar).

Bestuursleden

NaamPositieTenureCompensatieEigendom
Bo Liang
Chairman of the Board & GM13.9yrsCN¥3.05mgeen gegevens
Lingyin Kong
CTO & Executive Director8.4yrsCN¥1.40mgeen gegevens
Junchao Jiang
Executive Directorless than a yeargeen gegevensgeen gegevens
Xixiong Kang
Independent Non-Executive Director3.8yrsCN¥180.00kgeen gegevens
Wenbo Xu
Non-Executive Director6yrsgeen gegevensgeen gegevens
Weipeng Wang
Non-Executive Director8.2yrsgeen gegevensgeen gegevens
Yi Lin
Supervisor4.3yrsgeen gegevensgeen gegevens
Siu Wing Lam
Independent Non-Executive Director1.3yrsCN¥84.00kgeen gegevens
Shu Biu Yeung
Independent Non-executive Director1.3yrsCN¥70.00kgeen gegevens
Yang Ling
Non-executive Director1.3yrsgeen gegevensgeen gegevens
Lijuan Shi
Chairwoman of the Supervisory Board1.3yrsgeen gegevensgeen gegevens
Qiuping Zong
Supervisor1.3yrsgeen gegevensgeen gegevens

2.6yrs

Gemiddelde duur

43yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 2170 wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 2.6 jaar), wat duidt op een nieuw bestuur.